WO2008061671A3 - Use of an indazolemethoxyalkanoic acid for reducing triglyceride, cholesterol and glucose levels - Google Patents

Use of an indazolemethoxyalkanoic acid for reducing triglyceride, cholesterol and glucose levels Download PDF

Info

Publication number
WO2008061671A3
WO2008061671A3 PCT/EP2007/009908 EP2007009908W WO2008061671A3 WO 2008061671 A3 WO2008061671 A3 WO 2008061671A3 EP 2007009908 W EP2007009908 W EP 2007009908W WO 2008061671 A3 WO2008061671 A3 WO 2008061671A3
Authority
WO
WIPO (PCT)
Prior art keywords
cholesterol
glucose levels
reducing triglyceride
indazolemethoxyalkanoic
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2007/009908
Other languages
French (fr)
Other versions
WO2008061671A2 (en
Inventor
Angelo Guglielmotti
Giuseppe Biondi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Angelini Acraf SpA
Original Assignee
Aziende Chimiche Riunite Angelini Francesco ACRAF SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to UAA200905093A priority Critical patent/UA97123C2/en
Priority to DK07819835.5T priority patent/DK2097080T3/en
Priority to US12/444,442 priority patent/US8198310B2/en
Priority to EP07819835A priority patent/EP2097080B1/en
Priority to CA2666371A priority patent/CA2666371C/en
Priority to HK09108892.3A priority patent/HK1129071B/en
Priority to SI200731208T priority patent/SI2097080T1/en
Priority to BRPI0718522-7A priority patent/BRPI0718522A2/en
Priority to JP2009537517A priority patent/JP5192490B2/en
Priority to CN2007800432200A priority patent/CN101541323B/en
Priority to MX2009004295A priority patent/MX2009004295A/en
Application filed by Aziende Chimiche Riunite Angelini Francesco ACRAF SpA filed Critical Aziende Chimiche Riunite Angelini Francesco ACRAF SpA
Priority to AU2007323351A priority patent/AU2007323351B2/en
Priority to KR1020097010871A priority patent/KR101413616B1/en
Priority to EA200970506A priority patent/EA016885B1/en
Priority to ES07819835T priority patent/ES2403584T3/en
Priority to PL07819835T priority patent/PL2097080T3/en
Publication of WO2008061671A2 publication Critical patent/WO2008061671A2/en
Publication of WO2008061671A3 publication Critical patent/WO2008061671A3/en
Priority to IL198286A priority patent/IL198286A/en
Anticipated expiration legal-status Critical
Priority to US13/466,503 priority patent/US8846745B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Mixers Of The Rotary Stirring Type (AREA)

Abstract

Use of a compound of formula (I) in which R, R' and R' have the meanings given in the description, optionally in the form of a salt thereof with a pharmaceutically acceptable organic or mineral base, to prepare a pharmaceutical composition for reducing the blood triglyceride, cholesterol and glucose levels.
PCT/EP2007/009908 2006-11-24 2007-11-13 Use of an indazolemethoxyalkanoic acid for reducing triglyceride, cholesterol and glucose levels Ceased WO2008061671A2 (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
MX2009004295A MX2009004295A (en) 2006-11-24 2007-11-13 Use of an indazolemethoxyalkanoic acid to prepare a pharmaceutical composition.
US12/444,442 US8198310B2 (en) 2006-11-24 2007-11-13 Use of an indazolemethoxyalkanoic acid for reducing triglyceride, cholesterol and glucose levels
EP07819835A EP2097080B1 (en) 2006-11-24 2007-11-13 Use of an indazolemethoxyalkanoic acid for reducing triglyceride, cholesterol and glucose levels
CA2666371A CA2666371C (en) 2006-11-24 2007-11-13 Use of an indazolemethoxyalkanoic acid to prepare a pharmaceutical composition
HK09108892.3A HK1129071B (en) 2006-11-24 2007-11-13 Use of an indazolemethoxyalkanoic acid for reducing triglyceride, cholesterol and glucose levels
SI200731208T SI2097080T1 (en) 2006-11-24 2007-11-13 Use of an indazolemethoxyalkanoic acid for reducing triglyceride, cholesterol and glucose levels
AU2007323351A AU2007323351B2 (en) 2006-11-24 2007-11-13 Use of an indazolemethoxyalkanoic acid for reducing triglyceride, cholesterol and glucose levels
DK07819835.5T DK2097080T3 (en) 2006-11-24 2007-11-13 Use of an indazole methoxyalkanoic acid for the reduction of triglyceride, cholesterol and glucose levels
CN2007800432200A CN101541323B (en) 2006-11-24 2007-11-13 Use of an indazolemethoxyalkanoic acid for reducing triglyceride, cholesterol and glucose levels
UAA200905093A UA97123C2 (en) 2006-11-24 2007-11-13 Use of an indazolemethoxyalkanoic acid for reducing triglyceride, cholesterol and glucose levels
JP2009537517A JP5192490B2 (en) 2006-11-24 2007-11-13 Use of indazole methoxyalkanoic acid in the preparation of pharmaceutical compositions
BRPI0718522-7A BRPI0718522A2 (en) 2006-11-24 2007-11-13 USE OF A COMPOUND AND METHOD OF TREATMENT TO REDUCE BLOOD TRIGLYCERIDE, CHOLESTEROL AND / OR GLUCOSE LEVELS
KR1020097010871A KR101413616B1 (en) 2006-11-24 2007-11-13 Use of an indazolemethoxyalkanoic acid for reducing triglyceride, cholesterol and glucose levels
EA200970506A EA016885B1 (en) 2006-11-24 2007-11-13 Use of an indazolemethoxyalkanoic acid for treating a disease associated with triglyceride, cholesterol and/or glucose levels and method of treating said diseases
ES07819835T ES2403584T3 (en) 2006-11-24 2007-11-13 Use of an indazolmethoxyalkanoic acid to reduce triglyceride, cholesterol and glucose levels
PL07819835T PL2097080T3 (en) 2006-11-24 2007-11-13 Use of an indazolemethoxyalkanoic acid for reducing triglyceride, cholesterol and glucose levels
IL198286A IL198286A (en) 2006-11-24 2009-04-22 Use of an indazolemethoxyalkanoic acid for preparing pharmaceutical compositions for reducing triglyceride, cholesterol and glucose levels
US13/466,503 US8846745B2 (en) 2006-11-24 2012-05-08 Use of an indazolemethoxyalkanoic acid for reducing triglyceride, cholesterol and glucose levels

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT002254A ITMI20062254A1 (en) 2006-11-24 2006-11-24 USE OF A METHOXY-ALCANOIC ACID OF THE INZOL TO PREPARE A PHARMACEUTICAL COMPOSITION
ITMI2006A002254 2006-11-24

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/444,442 A-371-Of-International US8198310B2 (en) 2006-11-24 2007-11-13 Use of an indazolemethoxyalkanoic acid for reducing triglyceride, cholesterol and glucose levels
US13/466,503 Continuation US8846745B2 (en) 2006-11-24 2012-05-08 Use of an indazolemethoxyalkanoic acid for reducing triglyceride, cholesterol and glucose levels

Publications (2)

Publication Number Publication Date
WO2008061671A2 WO2008061671A2 (en) 2008-05-29
WO2008061671A3 true WO2008061671A3 (en) 2008-11-27

Family

ID=38198404

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/009908 Ceased WO2008061671A2 (en) 2006-11-24 2007-11-13 Use of an indazolemethoxyalkanoic acid for reducing triglyceride, cholesterol and glucose levels

Country Status (23)

Country Link
US (2) US8198310B2 (en)
EP (2) EP2097080B1 (en)
JP (1) JP5192490B2 (en)
KR (1) KR101413616B1 (en)
CN (1) CN101541323B (en)
AR (1) AR063894A1 (en)
AU (1) AU2007323351B2 (en)
BR (1) BRPI0718522A2 (en)
CA (1) CA2666371C (en)
CY (1) CY1116664T1 (en)
DK (2) DK2409698T3 (en)
EA (1) EA016885B1 (en)
ES (2) ES2530623T3 (en)
GE (1) GEP20125570B (en)
IL (1) IL198286A (en)
IT (1) ITMI20062254A1 (en)
MX (1) MX2009004295A (en)
PL (2) PL2097080T3 (en)
PT (2) PT2097080E (en)
SG (1) SG176508A1 (en)
SI (2) SI2409698T1 (en)
UA (1) UA97123C2 (en)
WO (1) WO2008061671A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20062254A1 (en) 2006-11-24 2008-05-25 Acraf USE OF A METHOXY-ALCANOIC ACID OF THE INZOL TO PREPARE A PHARMACEUTICAL COMPOSITION
GEP20135879B (en) 2009-08-03 2013-07-10 Aziende Chimiche Riunite Angelini Francesco A C R A F S P A It Method of 1-benzyl-3-hydroxymethyl-1h-indazole preparation, derivatives thereof, and required magnesium intermediates
US8999292B2 (en) 2012-05-01 2015-04-07 Translatum Medicus Inc. Methods for treating and diagnosing blinding eye diseases
WO2015173786A1 (en) * 2014-05-15 2015-11-19 Boyd Shelley Romayne Compositions and methods for treating and diagnosing ocular disorders
EP3990433A4 (en) 2019-06-25 2023-07-26 Translatum Medicus Inc. PROCESS FOR THE PREPARATION OF 2-((1-BENZYL-1H-INDAZOLE-3-YL)METHOXY)-2-METHYLPROPANIC ACID AND ITS DERIVATIVES
JP2023532888A (en) 2020-06-27 2023-08-01 クレセンタ バイオサイエンシズ Compositions and methods of use of compounds that modulate cellular metabolism
US12138243B2 (en) 2021-12-31 2024-11-12 Crescenta Biosciences Antiviral use of FABP4 modulating compounds

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0510748A1 (en) * 1991-04-22 1992-10-28 ANGELINI RICERCHE S.p.A. SOCIETA' CONSORTILE Use of a methoxy alkanoic acid of indazole for the manufacture of a medicament for the treatment of autoimmune diseases
WO1997016185A2 (en) * 1995-10-31 1997-05-09 Angelini Ricerche S.P.A. Societa' Consortile A pharmaceutical composition for the treatment of autoimmune diseases
WO1999004770A2 (en) * 1997-07-28 1999-02-04 AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (Trading also as ACRAF S.P.A.) A pharmaceutical composition active in reducing production of mcp-1 protein
WO2006117316A1 (en) * 2005-04-29 2006-11-09 Nycomed Gmbh Mutual prodrug compounds for use us antiinflammatory agents with gastrointestinal protective activity

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1131779B (en) * 1980-07-29 1986-06-25 Acraf SALT OF THE ACID (1-BENZYL-1H-INDAZOL-3-IL) -OXIACETIC WITH LYSINE AND PROCEDURE FOR ITS PREPARATION
IT1230441B (en) * 1989-02-07 1991-10-23 Acraf ETHERS OF THE INDAZOLE SERIES
US6077539A (en) * 1996-11-12 2000-06-20 Pozen, Inc. Treatment of migraine headache
IT1293794B1 (en) 1997-07-28 1999-03-10 Acraf DRUG ACTIVE IN REDUCING THE PRODUCTION OF MCP-1 PROTEIN
AU766219B2 (en) * 1998-02-02 2003-10-09 1149336 Ontario Inc. Method of regulating glucose metabolism, and reagents related thereto
DE19821625C1 (en) * 1998-05-15 2000-01-05 Merck Patent Gmbh Pharmaceutical preparation
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
ITFI20010230A1 (en) * 2001-11-29 2003-05-29 Menarini Int Operations Lu Sa PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF TYPE II DIABETES
US20060030582A1 (en) * 2002-04-29 2006-02-09 Demartino Julie Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity
EP1959982B1 (en) * 2005-12-01 2012-08-08 Flinders Technologies PTY. Ltd. Methods and compositions for preventing and/or treating pancreatitis
ITMI20062254A1 (en) 2006-11-24 2008-05-25 Acraf USE OF A METHOXY-ALCANOIC ACID OF THE INZOL TO PREPARE A PHARMACEUTICAL COMPOSITION

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0510748A1 (en) * 1991-04-22 1992-10-28 ANGELINI RICERCHE S.p.A. SOCIETA' CONSORTILE Use of a methoxy alkanoic acid of indazole for the manufacture of a medicament for the treatment of autoimmune diseases
WO1997016185A2 (en) * 1995-10-31 1997-05-09 Angelini Ricerche S.P.A. Societa' Consortile A pharmaceutical composition for the treatment of autoimmune diseases
WO1999004770A2 (en) * 1997-07-28 1999-02-04 AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (Trading also as ACRAF S.P.A.) A pharmaceutical composition active in reducing production of mcp-1 protein
WO2006117316A1 (en) * 2005-04-29 2006-11-09 Nycomed Gmbh Mutual prodrug compounds for use us antiinflammatory agents with gastrointestinal protective activity

Also Published As

Publication number Publication date
KR101413616B1 (en) 2014-07-01
EP2409698B1 (en) 2015-01-21
US20100069456A1 (en) 2010-03-18
PT2409698E (en) 2015-02-10
ES2530623T3 (en) 2015-03-04
ITMI20062254A1 (en) 2008-05-25
EP2409698A1 (en) 2012-01-25
US20120283307A1 (en) 2012-11-08
HK1129071A1 (en) 2009-11-20
HK1165275A1 (en) 2012-10-05
AR063894A1 (en) 2009-02-25
JP5192490B2 (en) 2013-05-08
GEP20125570B (en) 2012-07-10
CA2666371C (en) 2014-05-06
AU2007323351A1 (en) 2008-05-29
CY1116664T1 (en) 2017-03-15
CA2666371A1 (en) 2008-05-29
DK2409698T3 (en) 2015-04-27
BRPI0718522A2 (en) 2013-11-12
PL2097080T3 (en) 2013-07-31
US8846745B2 (en) 2014-09-30
DK2097080T3 (en) 2013-05-21
AU2007323351B2 (en) 2013-05-02
SI2409698T1 (en) 2015-04-30
PL2409698T3 (en) 2015-06-30
EA200970506A1 (en) 2009-10-30
JP2010510263A (en) 2010-04-02
IL198286A0 (en) 2010-02-17
MX2009004295A (en) 2009-05-05
EA016885B1 (en) 2012-08-30
EP2097080A2 (en) 2009-09-09
CN101541323B (en) 2012-01-04
EP2097080B1 (en) 2013-02-20
SI2097080T1 (en) 2013-05-31
KR20090081410A (en) 2009-07-28
PT2097080E (en) 2013-04-01
WO2008061671A2 (en) 2008-05-29
US8198310B2 (en) 2012-06-12
CN101541323A (en) 2009-09-23
UA97123C2 (en) 2012-01-10
IL198286A (en) 2016-03-31
SG176508A1 (en) 2011-12-29
ES2403584T3 (en) 2013-05-20

Similar Documents

Publication Publication Date Title
IL213613A (en) Pyrazine derivatives, compositions comprising the same and uses thereof
WO2007082808A3 (en) Thiazoles as 11 beta-hsd1 inhibitors
WO2009010416A3 (en) Inhibitors of 11b-hydroxysteroid dehydrogenase
WO2008124085A3 (en) Methods of using combinations of mek and jak-2 inhibitors
WO2008075068A3 (en) Acylaminopyrazoles as fgfr inhibitors
WO2008120725A1 (en) Novel pyrrolinone derivative and medicinal composition containing the same
WO2007107470A3 (en) Pyrazoles as 11-beta-hsd-1
FI4159217T3 (en) COMBINATION OF MEK INHIBITOR AND B-RAF INHIBITOR
MX2011012122A (en) Thiophene derivatives.
EP3091019A3 (en) Purine derivatives useful as hsp90 inhibitors
TW200833663A (en) Therapeutic agents
WO2007087204A3 (en) Heterocycles as nicotinic acid receptor agonists for the treatment of dyyslipidemia
WO2008143240A1 (en) Oral preparation comprising specific organic acid, and method for improvement in elution property and chemical stability of oral preparation
WO2008061671A3 (en) Use of an indazolemethoxyalkanoic acid for reducing triglyceride, cholesterol and glucose levels
MY140514A (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
WO2006077025A3 (en) Morpholines as 5ht2c agonists
WO2009068468A3 (en) Pyridine compounds
WO2011047055A8 (en) Novel mek inhibitors, useful in the treatment of diseases
EP1598341A8 (en) DPP-IV inhibitors
WO2007099171A3 (en) Bicyclo-pyrazoles active as kinase inhibitors
WO2007112913A3 (en) Benzimidazole derivatives
WO2005075471A3 (en) Thiazol-compounds as 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors
WO2006124413A3 (en) Methods for treating drug resistant cancer
WO2008023003A8 (en) Drug combinations for treating airway diseases
TW200800993A (en) Organic compounds

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780043220.0

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07819835

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2007323351

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2666371

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 198286

Country of ref document: IL

Ref document number: MX/A/2009/004295

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 12444442

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2007323351

Country of ref document: AU

Date of ref document: 20071113

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2009537517

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 1020097010871

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2007819835

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11327

Country of ref document: GE

Ref document number: 200970506

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 3686/CHENP/2009

Country of ref document: IN

ENP Entry into the national phase

Ref document number: PI0718522

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090507